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2Abstract 
 T helper 17 (Th17) cells that produce Interleukin (IL)-17A and IL-17F have been found to 
participate in the development of bronchial asthma and bleomycin-induced pulmonary fibrosis. 
However, whether they play a causative role in the airway remodeling observed in these 
respiratory diseases remains unclear. Because fibrocytes are involved in tissue repair and 
fibrosis, and are presumably precursors of lung fibroblasts and myofibroblasts, we examined the 
effects of IL-17A/F on fibrocyte functions. Both IL-17A and IL-17F enhanced fibrocytes' a-
smooth muscle actin (SMA) expression. Priming fibrocytes with IL-17A enhanced their 
 CD40-mediated IL-6 production, whereas IL-17F-priming increased the  CD40-mediated mRNA 
expression of collagen I, vascular endothelial growth factor (VEGF), and angiogenin.  CD4+ T 
cells co-cultured with fibrocytes produced IL-17A, which was inhibited by blocking  CD40 and 
 CD40 ligand interactions. These findings suggest that cooperative interactions between 
fibrocytes and Th17 cells play an important role via  CD40- and IL-17A/F-mediated signaling 
for collagen and proangiogenic factor production, which may lead to the extracellular matrix 
deposition and neo-vascularization seen in airway remodeling.
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31. Introduction 
 Fibrocytes are unique bone marrow-derived mesenchymal progenitor cells that are 
characterized byexpression of several markers of both hematopoietic cells (CD34, CD45, and 
 LSP-1) and stromal cells (collagen I and proly-4-hydroxylase). Fibrocytes are presumably 
derived from a subpopulation of  CD14+ peripheral blood monocytes  [1-5]. Fibrocytes are 
involved in chronic inflammation, tissue repair and fibrosis, and might be a significant source of 
lung fibroblasts and myofibroblasts in response to lung injury and in remodeling of the airway 
wall [6-12]. 
 Fibrocytes participate intissue remodeling by producing extracellular matrix proteins uch as 
collagen, and by secreting matrix metalloproteinases. Moreover, fibrocytes are an important 
source of inflammatory cytokines, chemokines and proangiogenic factors, such as vascular 
endothelial growth factor (VEGF) [13]. Fibrocytes express major histocompatibility complex 
class II and have shown antigen-presenting capabilities both in vitro and in vivo [2,3]. Recent 
data obtained from clinical setting suggest that the enumerating circulating fibrocytes may be a 
biomarker for disease progression i  chronic lung diseases including asthma nd pulmonary 
fibrosis  [14,15]. A greater understanding of the immunologic mediators that influence fibrocyte 
biology may suggest new opportunities for therapeutic manipulation of these cells in the process 
of fibrogenesis and neo-vascularization.
4 Interleukin (IL)-17A is the signature cytokine produced by the T helper 17 (Th17) cell subset. 
IL-17A expression has been implicated both in the pathogenesis of various autoimmune 
diseases and in some fibrotic disorders and the airway remodeling that occurs in chronic asthma 
[16-18]. IL-17 levels are increased in lung tissues, BAL fluids, sputum, and peripheral blood 
from patients with allergic asthma [19,20]. In the sputum of asthmatic patients, the increased 
levels of IL-17 mRNA expression were correlated with the number of neutrophils [21]. The 
percentages of  Th17 cells and the level of IL-17 in airway and plasma tend to increase with 
disease severity in asthmatic patients 
 Although IL-17 supposedly contributes to airway remodeling by contributing to the 
accumulation of neutrophils or the release of matrix metalloproteinases and cytokines including 
IL-6, TNF-a,  IL-11, HB-EGF by resident cells [17,22-24], much less is known about Th17 cells' 
ability to exacerbate airway remodeling and the mechanisms that may underlie this activity. 
Therefore, in this study we examined the effects of IL-17 on the proliferation and function of 
fibrocytes, and the mechanisms underlying Th17-mediated remodeling. Because it is difficult to 
obtain a sufficient number of fibrocytes with a high purity from pulmonary tissues, we took 
advantage of  CD14±-monocyte-derived fibrocytes to analyze the function of fibrocytes in vivo. 
We show that the cooperation between fibrocytes and Th17 cells may possibly play an 
important role in airway remodeling by  CD40/CD40 ligand interactions.
52. Materials and methods 
2.1. Cell culture 
 Peripheral blood was obtained from healthy volunteers with informed consent. The study was 
approved by the ethics committees of University of Fukui. 15 x 106 PBMCs isolated by 
Ficoll-Paque Plus (GE Healthcare Biosciences, Piscataway, NJ) were suspended in 2 ml of 
 RPMI1640 + 10% FBS + penicillin, and streptomycin (Invitrogen Co. Carlsbad, CA) and 
cultured in the wells of fibronectin-coated 6-well plates. After 48 h, non-adherent cells were 
removed and medium was changed periodically to develop fibrocytes, as previously described 
[10]. Non-adherent cells were washed out over time with changes of medium. 10 ng/ml of 
platelet derived growth factor-BB (PDGF-BB), VEGF, basic fibrocyte growth factor (bFGF), or 
Interleukin 113  (IL-1(3) (PeproTec Inc. Rocky Hill, NJ) was added on day 7. After 2 weeks of 
culture, fibrocytes were harvested and then washed twice. 1.2 x  105 cells and 0.6 x  105 cells 
were cultured in FCS-free  RPIM1640 in fibronectin-coated 12 and 24-well plates, respectively. 
Medium was replaced the next day with fresh FCS-free  RPIM1640. The cells were primed with 
10 ng/ml of IL-17A/E (PeproTec Inc.) for 1 hour and then were stimulated with 0.2  µg/ml of 
soluble  CD40 ligand  (sCD4OL; Alexis Biochemicals, San Diego, CA) in the presence or 
absence of dexamethasone (Sigma-Aldrich). After 48 h of stimulation, cell proliferation was 
assessed by adding a colorimetric assay reagent of Cell Counting Kit-8 (Dojindo, Kumamoto,
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Japan). The plates were incubated for 4 h at  37°C, and 450 nm  UV absorbance ofeach sample 
was measured ina microplate reader. Assay was done in triplicate wells. 
2.2. RNA isolation and RT-PCR 
 After 24 h culture with stimulation, total RNA were isolated using an RNeasy Mini Kit 
(QIAGEN K.K., Tokyo, Japan). First-strand cDNA was synthesized from 1  lug of total RNA 
using the Superscript First Strand System (Invitrogen Co.).  mRNA levels were quantified by 
real-time quantitative PCR using Taqman Pre-Developed Assay Reagents (Applied Biosystems 
Japan Ltd., Tokyo, Japan) according to the manufacturer's in tructions. For each sample, the 
difference in threshold cycle number between the target gene and 13-actin was used to determine 
the standardized xpression level (ACt). Subtracting the mean ACt of the control non-stimulated 
samples from the mean ACt of stimulated samples yielded the AACt value that was used to 
calculate relative xpression levels in the stimulated samples according to the formula 2-AAct. 
The error was estimated by evaluating the  2-AAct term using AACt ± SEM [25]. 
2.3. Flow cytometric analysis 
 Cells were pretreated with BD Cytofix/Cytoperm (BD Biosciences, San Diego, CA) and then 
incubated with anti-a-SMA mAb (Sigma-Aldrich Co.), and anti-collagen I mAb (Millipore
7Billerrica, MA), or isotype control IgG, along with human IgG in BD Permwash (BD 
Biosciences). After washing, FITC-conjugated F(ab')2 of goat anti-rabbit IgG (Rockland, 
Gilbertsville, PA) were added. Cells were analyzed on a FACSCalibur and CellQuest Pro (BD 
Biosciences), and specific mean fluorescence intensities (AMFI) were determined by subtracting 
the isotype-matched control antibody-fluorescence. Because the specific binding of anti-a-SMA 
mAb and anti-collagen I mAb to cells was not detectable without permeablization steps, the 
AMFI represents their intracellular expression levels.
2.4. T lymphocyte activation  by  fibrocytes 
 CD4+ T cells were isolated from PBMC by using a MACS  CD4+ T cell isolation Kit, 
according to the supplier's recommended protocol (Miltenyi Biotec, Bergisch Gladbach, 
Germany). A total of 0.3 x  105 fibrocytes were co-cultured with 1 x 106  CD4±T cells in the 
presence or absence of 1  jug/m1 of  anti-CD40 mAb or isotype-control IgG in the wells of 
fibronectin-coated 48-well plates. After 48 h, supernatants were collected.
 2.5. Cytokine measurements 
  IL-6,  IL-10, IFN-y, and 
Systems Inc., Minneapolis,
TGF-131 concentrations 
MN). IL-17 and VEGF
were 
levels
determined by ELISA 
were determined with
kits (R&D 
ELISA kits
8(Invitrogen Co.).
2.6. Statistical analysis 
 Comparisons of 2 groups used unpaired Student's t-tests, unless an F-test showed that the 
variances were significantly different. When variances were significantly different, Welch's test 
was used.  A  p value less than 0.05 denoted a statistically significant difference.
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3. Results 
3.1. Phenotypes  of  fibrocytes generated from PBMCs 
 Because only small numbers of fibroblast-like adherent cells developed from PBMCs using 
serum-based or serum-free culture conditions, we tested a variety of growth factors, which 
could be produced by fibrocyte in a autocrine fashion [2], including PDGF-BB, VEGF, bFGF, 
and IL-113, to maximize the fibrocyte yield and purity of adherent cells after 2 weeks of cultures. 
PDGF-BB enhanced the development of  CD14- fibroblast-like cells with a highest purity and 
quantity (Fig. 1A and B). Thus for the following experiments, PBMC were cultured in the 
presence of PDGF-BB for the last 7 days. The induced adherent cells expressed  a-SMA, 
calponin, collagen type I, and trace amounts of CD34, consisting with the typical phenotype of 
in vitro cultured fibrocytes [3]. Although they also expressed MHC class II, CD86 and  CD40, 
they did not expressed other cell lineage markers (i.e. dendritic cells; CD1 and CD83, 
 monocytes;  CD14, endothelial cells; Willbrand factor, T cells; CD3 and B cells;  CD19) (Fig 
1C). 
3.2. Large amounts of  IL-17A/F enhance fibrocyte proliferation. 
 It has been shown that Th2 cytokines, IL-4 and IL-13 augmented fibrocyte differentiation 
from  CD14+ precursors whereas the  Thlcytokine interferon-y inhibits differentiation [26], and 
that activated T-cell subsets enhanced fibrocyte outgrowth depended on cell-contacts with
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 CD14+ precursors  [1]. Consistent with the previous reports, 10 ng/ml of IL-13 increasedthe 
proliferation of fibrocytes, whereas  IFN-y decreased it (Fig 2A). Lower concentrations of 
IL-17A and IL-17F did not show any significant effects on the fibrocyte proliferation, while 
higher concentrations of IL-17A and IL-17F (50 ng/ml) enhanced fibrocyte proliferation (Fig 
2B). Stimulation with a soluble form of  CD40 ligand (sCD4OL), which is expressed on 
activated T cells, augmented the proliferation of both IL-17A/F-treated and non-treated 
fibrocytes. 
3.3.  IL-17A/F enhanced a-SMA and collagen expression. 
 Both IL-17A and IL-17F slightly, but consistently increased the constitutive expression of 
 a-SMA, indicating that they directly induced maturation of fibrocytes. Stimulation with 
sCD4OL also enhanced a-SMA expression irrespective of IL-17A/F-priming (Fig. 3A). Neither 
IL-17A nor IL-17F alone increased collagen I production in terms of the mRNA and protein 
levels, but both enhanced intracellular collagen I and mRNA expression in response to sCD4OL 
stimulation (Fig. 3B and 3C). 
3. 4.  IL-17A and  IL-17F differentially regulate cytokine production  by  fibrocytes. 
 The fibrocytes constitutively produced IL-6,  IL-10 and  TGF-131 (Fig 4A - 4C). Production of
11
IL-6 and  IL-10 was enhanced by stimulation with  sCD4OL, whereas  TGF-131 production was 
inhibited. Neither IL-17A nor IL-17F alone increased IL-6 production. Of note, priming with 
IL-17A but not IL-17F increased  sCD4OL-mediated IL-6 production. In addition, both IL-17A 
and IL-17F decreased  IL-10 and  TGF-131 production i  a dose-dependent manner, irrespective 
 sCD4OL-stimulation. Neither IL-17A nor IL-17F alone showed any effects on theconstitutive 
mRNA expressions of VEGF and angiogenin (Fig. 4D and 4F). Priming with IL-17F, but not 
IL-17A significantly enhanced the mRNA expressions ofVEGF and angiogenin conjunction 
with  sCD4OL. Although IL-17A and IL-17F are known to bind to the same receptor, they might 
have distinct roles in priming fibrocytes.
3.5. Interactions between fibrocytes and  CD4+ T cells results in  IL-17 production. 
 Because of their expression of MHC class II molecules and CD86, fibrocyte can presumably 
stimulate effector  CD4+ T cells as antigen presenting cells. Thus, we asked whether fibrocytes 
interacted with  CD4+ T cells. As shown in Fig. 5, when cultured alone, both fibrocytes and 
 CD4+ T cells produced little, if any IL-17 and IFN-y. However, when  CD4+ T cells and 
fibrocytes were co-cultured, these cytokines were produced. IL-17 production, but not IFN-y 
production by  CD4+ T cells co-cultured with fibrocytes was inhibited by  anti-CD40 blocking 
antibody, indicating that  CD40/CD4OL interactions were involved in IL-17 production rather
12
than IFN-y production.
3.6. Dexamethasone suppressed a-smooth muscle actin expression and cytokine production 
 by  fibrocytes. 
 The possible therapeutic effects of glucocorticoid on airway remodeling remain controversial. 
In our system, dexamethasone i hibited IL-17A/F-induced up-regulation of a-smooth muscle 
actin expression, irrespective ofstimulation with sCD4OL (Fig. 6A). Dexamethasone suppressed 
the IL-6 production that was enhanced by sCD4OL and the constitutive and inducible  IL-10 
production in a dose dependent manner (Fig. 6B, 6C). Constitutive  TGF-131 productions was 
also suppressed bydexamethasone, butwith a lesser extent (Fig. 6D)
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4. Discussion 
 In the present study, we have demonstrated that IL-17A and IL-17F can modulate fibrocyte 
functions to induce pro-angiogenic cytokine and collagen production in response to  CD40 
signaling and allows these cells to differentiate into a myofibroblastic phenotype, suggesting 
proangiogenic and profibrogenic roles of IL-17A/F in tissue remodeling. IL-17A and IL-17F 
share the high amino acid sequence homology and bind to the same two receptors, such as 
IL-17RA and  IL17RC. IL-17A has a higher binding affinity for IL-17RA, whereas IL-17F has a 
higher affinity for IL-17RC. Thus, they perform overlapping functions, but they also have 
distinct functions [27]. Consistent with the notion, IL-17A and IL-17F differentially primed 
fibrocytes in terms of  CD40-mediated IL-6 and VEGF production and the mRNA expression of
angiogenin. 
 TGF-131 is known to be a pleiotropic growth factor that directly induces a variety of responses 
associated with lung fibrosis and airway remodeling [28]. Wilson et  al. reported that IL-17A, 
production of which is dependent on  TGF-I31, was essential for the development of 
bleomycin-induced pulmonary fibrosis and speculated that the profibrogenic activity of TGF-131 
may be partially attributed tothe induction of IL-17A [29]. Because IL-17A/F inhibited  TGF-I31 
production by fibrocytes, the profibrogenic effects of IL-17A/F, such as  a-smooth muscle 
expression and collagen production could not be attributed to the endogenous  TGF-131
14
production. 
 Several cytokines, including IL-6 have been implicated in the differentiation, expansion 
and/or survival of Th17 cells [30]. Recently, it has been shown that a Th17 response was much 
more dependent on  CD40-mediated T cell-APC interactions than was a  Thl response [31]. 
Since fibrocytes are known to function as an antigen-presenting cell[32], crosstalk between T
cells and fibrocytes through CD4OL expression and IL-6 production, respectively, might 
augment a  Th17 response rather than a  Thl response. 
 Although whether PDGF directly induced the differentiation ofmonocytes into fibrocytes or 
prevented fibrocyte lineage-committed cells from undergoing apoptosis was not determined, 
culturing PBMC in the presence of PDGF-BB yields a high quantity and purity of fibrocytes. 
Airway smooth muscle cell-derived PDGF has been shown to promote fibrocyte migration to 
smooth muscle bundles in vitro [33]. PDGF might play an important role in the accumulation f 
fibrocytes in the airway smooth muscle compartment i  asthma. 
 Asthmatic subjects exhibit increased numbers of VEGF mRNA-expressing cells in the 
bronchial mucosa, which are correlated with the degree of vascularity.  CD34+ cells were one of 
the major sources of VEGF and angiogenin within the bronchial mucosa of asthmatics  [34]. 
Although IL-17F alone cannot directly stimulate the growth of vascular endothelial cells [35], 
IL-17F and CD4OL expressed by activated Th17 cells might participate inneovascularization n
15
asthmatic airway by enhancing VEGF and angiogenin expression by  CD34+ fibrocytes. 
 Accumulating evidence suggests that aberrant IL-17 production is a key determinant of 
severe forms of asthma [36]. A recent study indicated that airway hyper-reactive responses 
induced by transferred Th17 cells are steroid-resistant [37]. In patients with chronic kidney 
diseases, it has been shown that the number of interstitial fibrocytes was significantly decreased 
by glucocorticoid therapy [38]. Given that cytokine production and a-SMA expression by 
fibrocytes were susceptible to the inhibitory effects of glucocorticoids, fibrocyte-mediated 
airway remodeling might be alleviated by steroid-treatment, irrespective of the involvement of 
 IL-17A/F. 
 In conclusion, cooperativity between fibrocytes and Th17 cells may play an important role 
via  CD40- and IL-17A/F-mediated signaling for collagen and proangiogenic factor production, 
which may lead to extracellular matrix deposition, basement membrane thickening, and the 
neo-vascularization observed in airway remodeling. These fibrocyte-mediated responses in 
airway remodeling might be ameliorated by glucocorticoid treatment.
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Figure legends 
Figure 1 Phenotypes of fibrocytes generated from PBMCs 
Fibrocytes were generated from  1X107 PBMCs in the presence of the indicated growth factors. 
(A) The numbers of fibrocytes (hatched bars) and  CD14+ macrophages (open bars) are shown 
after two weeks of culture. The data are expressed as means ± SEM (n = 4). (B) Morphology 
and (C) lineage marker expression of the fibrocytes generated in the presence of PDGF-BB 
were analyzed by phase-contrast microscopy and flow cytometric, respectively. Cells were 
stained with the indicated lineage marker-specific Ab (thick lines) or isotype control Ab (thin 
lines).
Figure 2 Effects of IL-17A/F and  CD40-stimulation on fibrocyte proliferation 
Fibrocytes were cultured (A) in the presence of 10 ng/ml of the indicated cytokines or (B) in the 
presence of various concentration of IL-17A (closed symbols) or IL-17F (open symbols) with 
(circles) or without (squares) sCD4OL. After 2 days of culture, relative cell proliferation was 
determined by a colorimetric assay. The data are expressed as means ± SEM (n = 4). *p < 0.05
Figure 3 Effects of IL-17A/F on a-smooth muscle actin and collagen expression 
Fibroblasts were primed with IL17A/F and then stimulated with (hatched bars) or without (open
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bars) sCD4OL. (A) Intracellular  oc-smooth muscle actin expression and (B) collagen I expression 
were quantified by flow cytometry after 2 days of culture. (C) Collagen I mRNA expression 
was determined by real-time PCR. The indicated relative xpression levels and the errors were 
calculated with the formula  TAAct. Results are means ± SEM (n = 4). *p < 0.05 
Figure 4 Effects of IL-17A/F on constitutive and  CD40-mediated cytokine production by 
fibrocytes 
Fibrocytes were primed with IL17A (closed symbols) or IL-17F (open symbols) and then 
stimulated with (circles) or without (squares)  sCD40L. After 2 days of culture, (A) IL-6, (B) 
 IL-10, (C)  TGF-(31, and (D) VEGF concentrations in the supernatants were determined by 
ELISA. (E) VEGF and (F) angiogenin  mRNA expression by fibrocytes timulated with (hatched 
bars) or without (open bars) sCD4OL was determined by real-time PCR. The indicated relative 
expression levels and the errors were calculated with the formula  TAAct. Results are means 
 ±  SEM  (n  =  4).  *p  <  0.05,  **p  <  0.01 
Figure 5 IL-17 and  IFN-y production by  CD4+ T cells co-cultured with  fibrocytes 
 CD4+ T cells were co-cultured with fibrocytes in the presence or absence of  anti-CD40 blocking 
Ab or control mouse  IgG1  . IL-17 and IFN-y concentrations i  supernatants were determined by
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ELISA. Results are means ± SEM (n = 4). *p < 0.05, nd; not detected 
Figure 6 Dexamethasone inhibited a-smooth muscle actin and cytokine production by 
fibrocytes. 
Fibrocytes primed with IL-17A (closed symbols) or IL-17F (open symbols) were stimulated 
with (circles) or without (squares) sCD4OL in the presence of 1  iuM or the indicated 
concentrations of dexamethasone. After 2 days of culture, (A) a-smooth muscle actin 
expression was determined by flow cytometry and (B) IL-6, (C)  IL-10, and (D) TGF-131 
concentrations in  supernatants were determined by ELISA. Results are means ± SEM (n = 4). 
 *p  <  0.05,  **p  <  0.01
